Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|October 1, 2006

Applied Clinical Trials

  • Applied Clinical Trials-10-01-2006
  • Volume 0
  • Issue 0

eShowcase: GlobalView EventNet

System enables IRB members to review ?s in near real-time from anywhere in the world

System enables IRB members to review AEs in near real-time from anywhere in the world

GlobalView EventNet

PPD, Inc. (Wilmington, NC) just released a customizable, global event management and adjudication system for quick review of safety and endpoint-driven data from large clinical trials or registries. The secure, Internet-based system provides broad access to adverse event data, particularly in studies with multiple information sources and ones that need review by a board of independent physicians.

GlobalView EventNet provides access to data in near real-time and allows IRB members to examine the data at their own convenience from any location around the world. The board members can also request follow-up information or confirm adjudicated events through an online interface. GlobalView EventNet also sends automatic email alerts to prompt and encourage timely review. The system electronically compares each IRB member's decision and documents them per established guidelines.

PPD, Inc., (910) 251-0081, www.ppdi.com

Articles in this issue

about 20 years ago

Assessing Safety in Clinical Trials

about 20 years ago

eShowcase: eCTDXPress Aspire

about 20 years ago

eShowcase: LabPas CT 2.5

about 20 years ago

Informed Consent Considerations

about 20 years ago

Broad Introduction to CTs

about 20 years ago

CDISC Standards Energize EDC

Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.